S&P 500   3,003.05 (-0.12%)
DOW   26,862.68 (+0.13%)
QQQ   192.36 (-0.53%)
AAPL   240.85 (+0.14%)
FB   183.58 (-3.26%)
MSFT   137.14 (-0.93%)
GOOGL   1,242.95 (-0.11%)
AMZN   1,765.75 (-1.11%)
NVDA   196.88 (+0.44%)
BABA   169.89 (-2.09%)
GE   8.96 (+1.93%)
TSLA   256.34 (+1.12%)
T   38.19 (-0.10%)
F   9.06 (+0.33%)
ACB   3.61 (-2.17%)
PRI   125.78 (+0.07%)
NFLX   267.76 (-3.70%)
BAC   31.20 (+0.58%)
GILD   66.11 (+1.38%)
DIS   132.79 (+1.94%)
S&P 500   3,003.05 (-0.12%)
DOW   26,862.68 (+0.13%)
QQQ   192.36 (-0.53%)
AAPL   240.85 (+0.14%)
FB   183.58 (-3.26%)
MSFT   137.14 (-0.93%)
GOOGL   1,242.95 (-0.11%)
AMZN   1,765.75 (-1.11%)
NVDA   196.88 (+0.44%)
BABA   169.89 (-2.09%)
GE   8.96 (+1.93%)
TSLA   256.34 (+1.12%)
T   38.19 (-0.10%)
F   9.06 (+0.33%)
ACB   3.61 (-2.17%)
PRI   125.78 (+0.07%)
NFLX   267.76 (-3.70%)
BAC   31.20 (+0.58%)
GILD   66.11 (+1.38%)
DIS   132.79 (+1.94%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space
(ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 TAIWAN LIPOSOME/SAbeona TherapeuticsAldeyra TherapeuticsKala PharmaceuticalsMustang Bio
SymbolNASDAQ:TLCNASDAQ:ABEONASDAQ:ALDXNASDAQ:KALANASDAQ:MBIO
Price Information
Current Price$5.20$2.44$5.99$3.62$2.88
52 Week RangeBuyBuyBuyBuyBuy
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$10.67$19.67$30.33$21.80$10.67
% Upside from Price Target105.13% upside706.01% upside406.40% upside502.21% upside270.37% upside
Trade Information
Market Cap$168.10 million$107.01 million$161.07 million$114.27 million$120.54 million
BetaN/A1.950.862.142.1
Average Volume1,656638,515215,859281,553238,793
Sales & Book Value
Annual Revenue$2.04 million$3 millionN/AN/AN/A
Price / Sales81.6240.11N/AN/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$0.69 per share$2.80 per share$3.30 per share$3.11 per share$1.32 per share
Price / Book7.540.87N/AN/AN/A
Profitability
Net Income$-29,450,000.00$-56,670,000.00$-38,890,000.00$-66,740,000.00$-30,660,000.00
EPS($0.47)($1.19)($1.79)($2.48)($1.14)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-406.97%N/AN/AN/AN/A
Return on Equity (ROE)-155.55%-59.99%-69.24%-117.68%-86.70%
Return on Assets (ROA)-66.81%-46.25%-61.44%-52.43%-66.79%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.73%0.06%N/A1.16%0.21%
Current Ratio2.69%2.54%11.40%7.50%13.10%
Quick Ratio2.69%2.54%11.40%7.04%13.10%
Ownership Information
Institutional Ownership Percentage2.11%58.73%61.26%68.67%26.89%
Insider Ownership PercentageN/A33.60%13.50%30.77%1.70%
Miscellaneous
EmployeesN/AN/AN/A13038
Shares Outstanding32.02 million49.32 million27.58 million34.01 million40.45 million
Next Earnings Date11/25/2019 (Estimated)11/8/2019 (Estimated)11/13/2019 (Estimated)11/14/2019 (Estimated)11/12/2019 (Estimated)
OptionableNot OptionableOptionableOptionableOptionableOptionable
 TAIWAN LIPOSOME/SAbeona TherapeuticsAldeyra TherapeuticsKala PharmaceuticalsMustang Bio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel